These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

820 related articles for article (PubMed ID: 19379060)

  • 21. Prasugrel: a novel platelet ADP P2Y receptor antagonist.
    Wilson W; Gurvitch R; Ajani AE
    Cardiovasc Ther; 2009; 27(3):194-8. PubMed ID: 19689619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel antiplatelet strategies in acute coronary syndromes.
    Sabatine MS
    Cleve Clin J Med; 2009 Apr; 76 Suppl 1():S8-15. PubMed ID: 19332592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. P2Y12 inhibitors in cardiovascular disease: focus on prasugrel.
    Scott DM; Norwood RM; Parra D
    Ann Pharmacother; 2009 Jan; 43(1):64-76. PubMed ID: 19050170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.
    Chin CT; Roe MT; Fox KA; Prabhakaran D; Marshall DA; Petitjean H; Lokhnygina Y; Brown E; Armstrong PW; White HD; Ohman EM;
    Am Heart J; 2010 Jul; 160(1):16-22.e1. PubMed ID: 20598967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice.
    Thomas D; Giugliano RP
    Crit Pathw Cardiol; 2009 Mar; 8(1):12-9. PubMed ID: 19258833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prasugrel for acute coronary syndromes: faster, more potent, but higher bleeding risk.
    Lazar LD; Lincoff AM
    Cleve Clin J Med; 2009 Dec; 76(12):707-14. PubMed ID: 19952295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasugrel.
    Martin MT; Spinler SA; Nutescu EA
    Clin Ther; 2011 Apr; 33(4):425-42. PubMed ID: 21635989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction.
    Morrow DA; Wiviott SD; White HD; Nicolau JC; Bramucci E; Murphy SA; Bonaca MP; Ruff CT; Scirica BM; McCabe CH; Antman EM; Braunwald E
    Circulation; 2009 Jun; 119(21):2758-64. PubMed ID: 19451347
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention.
    Robinson A; Das K; Koshy SK; Das P
    Future Cardiol; 2009 May; 5(3):237-46. PubMed ID: 19450050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prasugrel: a guide to its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in the US.
    Lyseng-Williamson KA
    Am J Cardiovasc Drugs; 2012 Jun; 12(3):207-16. PubMed ID: 22583148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38.
    Mahoney EM; Wang K; Arnold SV; Proskorovsky I; Wiviott S; Antman E; Braunwald E; Cohen DJ
    Circulation; 2010 Jan; 121(1):71-9. PubMed ID: 20026770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prasugrel (Effient) vs. clopidogrel (Plavix).
    Med Lett Drugs Ther; 2009 Sep; 51(1320):69-70. PubMed ID: 19738549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prasugrel: a new antiplatelet drug for the prevention and treatment of cardiovascular disease.
    Koo MH; Nawarskas JJ; Frishman WH
    Cardiol Rev; 2008; 16(6):314-8. PubMed ID: 18923235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current oral antiplatelets: focus update on prasugrel.
    John J; Koshy SK
    J Am Board Fam Med; 2012; 25(3):343-9. PubMed ID: 22570398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile.
    Jakubowski JA; Winters KJ; Naganuma H; Wallentin L
    Cardiovasc Drug Rev; 2007; 25(4):357-74. PubMed ID: 18078435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unmet needs in oral antiplatelet therapy with ADP receptor blocking agents.
    Husted S
    Fundam Clin Pharmacol; 2009 Feb; 23(1):1-9. PubMed ID: 19267766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prasugrel development - claims and achievements.
    Serebruany V; Shalito I; Kopyleva O
    Thromb Haemost; 2009 Jan; 101(1):14-22. PubMed ID: 19132184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study.
    Montalescot G; Sideris G; Cohen R; Meuleman C; Bal dit Sollier C; Barthélémy O; Henry P; Lim P; Beygui F; Collet JP; Marshall D; Luo J; Petitjean H; Drouet L
    Thromb Haemost; 2010 Jan; 103(1):213-23. PubMed ID: 20062936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
    Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
    Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study.
    Trenk D; Stone GW; Gawaz M; Kastrati A; Angiolillo DJ; Müller U; Richardt G; Jakubowski JA; Neumann FJ
    J Am Coll Cardiol; 2012 Jun; 59(24):2159-64. PubMed ID: 22520250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.